Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
第一作者:
Edward C,Keystone
第一单位:
Mount Sinai Hospital, 60 Murray Street, Toronto, ON, Canada. edkeystone@mtsinai.on.ca
作者:
主题词
抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);关节造影术(Arthrography);残疾鉴定(Disability Evaluation);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);健康状况(Health Status);人类(Humans);免疫球蛋白Fab片段(Immunoglobulin Fab Fragments);关节(Joints);男(雄)性(Male);甲氨蝶呤(Methotrexate);中年人(Middle Aged);聚乙烯二醇类(Polyethylene Glycols);功能恢复(Recovery of Function);疾病严重程度指数(Severity of Illness Index);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1093/rheumatology/kes082
PMID
22596211
发布时间
2022-04-08
- 浏览18

Rheumatology (Oxford, England)
1628-38页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文